Previous studies in the rodent have shown that the cytokine @entity1192 can act within the brain to influence peripheral @entity650 secretion. In order to determine if such an interaction occurs in the primate, we have compared the effects of intracerebroventricular vs. intravenous injection of @entity1356 on the release of @entity650 into the peripheral circulation of the monkey. The effects of i.c.v. @entity1356 on the release of the @entity1193 ( @entity1193 ) were studied in parallel. For comparison, we have also measured the release of both @entity650 and @entity1193 into lumbar CSF after i.c.v. @entity1356 injection. Ten ovariectomized @entity2608 with indwelling lateral ventricular and peripheral venous cannulae were studied. @entity1 @entity3426 (400 ng) was infused either i.c.v. or i.v. over 30 min and blood samples were collected for @entity650 and @entity1193 measurement by monoclonal human ELISAs. Although both i.c.v. and i.v. @entity1356 stimulated @entity650 and @entity1193 release into peripheral blood, the stimulation was much more profound after i.c.v. injection (p < 0.001). Peak @entity650 levels were 2010 +/- 590 pg/ml after i.c.v. @entity1356 compared to 243 +/- 60 pg/ml after i.v. @entity1356 . Peak @entity1193 levels were 61,310 +/- 16,190 pg/ml after i.c.v. @entity1356 compared to 18,175 +/- 4270 pg/ml after i.v. @entity1356 . There was no significant effect of an i.c.v. saline infusion on peripheral @entity650 or @entity1193 levels. In four animals, lumbar CSF was collected 7 h after i.c.v. @entity1356 injection. The mean concentration of @entity650 in CSF was 103, 570 +/- 13,780 pg/ml after i.c.v. @entity1356 vs. 224 +/- 190 pg/ml after i.c.v. saline injection; @entity1193 was 47,460 +/- 6290 pg/ml vs. 1040 +/- 550 pg/ml. As expected, both i.c.v. and i.v. IL-beta stimulated ACTH and @entity701 release; the stimulation was significantly greater after i.c.v. compared to i.v. administration (p < 0.001). Thus, in the monkey, i.c.v. injection of @entity1356 stimulates the release of large amounts of @entity650 and @entity1193 into the CSF and the peripheral circulation. Both @entity650 and @entity1193 were released into the peripheral circulation to a much greater extent after i.c.v. compared to i.v. @entity1356 infusion. These studies provide further support in the primate for a mechanism by which @entity32 within the brain could induce a variety of systemic responses.

Intracerebroventricular injection of XXXX stimulates the release of high levels of @entity650 and @entity1192 receptor antagonist into peripheral blood in the primate.

@entity1 :: ('9606', 'Species') :: ['Human'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1356 :: ('3553', 'Gene') :: ['IL-1beta'] @entity1193 :: ('3557', 'Gene') :: ['IL-1ra', 'IL-1 receptor antagonist'] @entity1192 :: ('3552', 'Gene') :: ['IL-1'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['rIL-1beta'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity2608 :: ('9544', 'Species') :: ['rhesus monkeys']
@entity1192 :: (3552,Gene) :: ['interleukin-1']
